Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
![[99mTc]Tc-6–1 in Triple Negative Breast Cancer: NCT07784660 Clinical Landscape Report 2026](https://synapse-static-patsnap-com.libproxy1.nus.edu.sg/strapi-static/Blog_cover_12_7f0c44f64f.jpg)
9 min read
[99mTc]Tc-6–1 in Triple Negative Breast Cancer: NCT07784660 Clinical Landscape Report 2026
11 September 2026
NCT07784660 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Mercaptopurine in Hereditary Leiomyomatosis and Renal Cell Cancer: NCT07716735 Clinical Landscape Report 2026
11 September 2026
NCT07716735 clinical landscape for Hereditary Leiomyomatosis and Renal Cell Cancer: endpoints, sponsor, phase, geography, readouts, asset context and develop…
9 min read
HRS-4642 in Pancreatic Cancer: NCT07806058 Clinical Landscape Report 2026
11 September 2026
NCT07806058 clinical landscape for Pancreatic Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Calcipotriene in Plaque psoriasis: NCT07780929 Clinical Landscape Report 2026
11 September 2026
NCT07780929 clinical landscape for Plaque psoriasis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Claseprubart in Myasthenia Gravis: NCT07647510 Clinical Landscape Report 2026
11 September 2026
NCT07647510 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
TJ-102 (Phrontline) in Ovarian Cancer: NCT07778498 Clinical Landscape Report 2026
11 September 2026
NCT07778498 clinical landscape for Ovarian Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Daratumumab in Relapse multiple myeloma: NCT07764861 Clinical Landscape Report 2026
11 September 2026
NCT07764861 clinical landscape for Relapse multiple myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Bupropion Hydrochloride in Metabolic Syndrome: NCT07806279 Clinical Landscape Report 2026
11 September 2026
NCT07806279 clinical landscape for Metabolic Syndrome: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Cemiplimab-RWLC in Non-small cell lung cancer stage I: NCT07808138 Clinical Landscape Report 2026
11 September 2026
NCT07808138 clinical landscape for Non-small cell lung cancer stage I: endpoints, sponsor, phase, geography, readouts, asset context and development white sp…
9 min read
Resmetirom in Metabolic Dysfunction Associated Steatohepatitis: NCT07680478 Clinical Landscape Report 2026
11 September 2026
NCT07680478 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Ipilimumab in Mesothelioma, Malignant: ACTRN12626000505303 Clinical Landscape Report 2026
11 September 2026
ACTRN12626000505303 clinical landscape for Mesothelioma, Malignant: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tunlametinib in NRAS Mutant Melanoma: NCT07750067 Clinical Landscape Report 2026
11 September 2026
NCT07750067 clinical landscape for NRAS Mutant Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.